Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) EBT (2016 - 2025)

Historic EBT for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to -$1.2 million.

  • Arcadia Biosciences' EBT rose 253.81% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year decrease of 27743.59%. This contributed to the annual value of -$4.3 million for FY2024, which is 1901.9% up from last year.
  • Arcadia Biosciences' EBT amounted to -$1.2 million in Q3 2025, which was up 253.81% from -$501000.0 recorded in Q2 2025.
  • Over the past 5 years, Arcadia Biosciences' EBT peaked at $3.2 million during Q2 2023, and registered a low of -$13.8 million during Q4 2021.
  • Over the past 5 years, Arcadia Biosciences' median EBT value was -$2.3 million (recorded in 2022), while the average stood at -$3.0 million.
  • In the last 5 years, Arcadia Biosciences' EBT skyrocketed by 18311.83% in 2023 and then plummeted by 80539.33% in 2024.
  • Arcadia Biosciences' EBT (Quarter) stood at -$13.8 million in 2021, then surged by 77.05% to -$3.2 million in 2022, then surged by 85.95% to -$445000.0 in 2023, then tumbled by 805.39% to -$4.0 million in 2024, then skyrocketed by 71.41% to -$1.2 million in 2025.
  • Its EBT was -$1.2 million in Q3 2025, compared to -$501000.0 in Q2 2025 and $530000.0 in Q1 2025.